Immunotherapy Drugs Market - Global Outlook & Forecast 2021-2026

Immunotherapy Drugs Market - Global Outlook & Forecast 2021-2026

In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Immunotherapy Drugs Market Report

The global immunotherapy drugs market was valued at USD 169.47 billion in 2020 and is expected to reach USD 326.36 billion by 2026, growing at a CAGR of 11.54%.

The major factor responsible for growth in the immunotherapy drugs industry is an increase in demand for outsourcing the manufacturing of immunotherapy drugs by several biopharmaceuticals and biotechnological companies and resistance against conventional treatments. Major key players and other prominent vendors engaged in the immunotherapy drugs domain are constantly focussing on product launches, product approvals, R&D activities, and expanding their organic growth.

The following factors are likely to contribute to the growth of the global immunotherapy market during the forecast period:
Next-generation immunotherapies
COVID-19 as a catalyst
Investment in research & development activities
Mergers & acquisitions
Surge of CAR-T therapies


The emergence of various diseases in developing countries is propelling the usage of monoclonal antibodies, demanding the introduction of newer immunotherapies and creating opportunities for the market.
Cancer immunotherapy drugs revolutionized in cancer therapies that have begun to shift curve of cancer patients by increasing their lifespan.
The increasing immunotherapy drugs pipeline coupled with the emergence of the pandemic has scaled up the production of medicines.
By product, the adoptive cell therapy segment is expected to witness absolute growth of 1280% during the forecast period.
The recent trend of mergers and acquisitions is boosting the growth of the immunotherapy drugs industry. For instance, Bristol-Myers Squibb’s one of most recent and high-value transactions was the acquisition of Celgene in January 2018.

The study considers a detailed scenario of the present global immunotherapy drugs market and its market dynamics for the period 2021−2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.


This research report includes a detailed segmentation by


The monoclonal antibody segment accounted for the high share of 72.6% of the global immunotherapy drugs market in 2020. Significant advances in the field, notably, and the unprecedented results obtained using monoclonal antibodies that attach themselves to lymphocytes. This restores their functioning toward tumor cell and thus create a defense for the body against cancer.
The autoimmune diseases segment accounted for the highest market share in 2020. It is expected to post an incremental growth of USD 23.95 billion with 33% absolute growth during the forecast period. The segment's growth is attributed to the increase in the prevalence of immune-mediated inflammatory diseases (IMIDs), including autoimmune and auto-inflammatory diseases.
In 2020, the cancer segment accounted for the highest market share of 45.33%. Immunotherapies in oncology have been widely popularized by developing curative therapies, such as CAR T-cell. However, developing personalized therapies such as CAR T-cell to treat various types of cancers may pose significant challenges, such as educating medical personnel regarding the procedures and creating a convenient process for engineering T-cells of the patients and infusing them.

Segmentation by Product
Monoclonal Antibodies
Immune System Modulators
Car T-Cell Therapies

Segmentation by Application
Auto Immune & Inflammatory Disease


North America: North America has the highest share among all the regions and is likely to witness an absolute growth of around 105% during the forecast period. The rise in the immunotherapy drugs industry is primarily attributable to the increasing incidence rates of various types of cancers such as non-Hodgkin lymphoma, Hodgkin lymphoma, melanoma of the skin, and leukemia, etc.
Europe: Europeans represent about one-tenth of the global population, yet one in four of all cancer diagnoses occur in this region. This region is likely to witness an absolute growth of around 84% during the forecast period.
APAC: APAC is witnessing growing demand mainly due to a large and growing population. In APAC, various opportunities associated with the growth of the cancer immunotherapy drugs market are increasing, and government initiatives will further improve the healthcare sector.

Segmentation by Geography

North America
South Korea
Latin America
Middle East & Africa
South Africa
Saudi Arabia


The major vendors such as F. Hoffmann-La Roche, Bristol Myers Squibb Company, Merck & Co., Inc., GlaxoSmithKline, Novartis, AstraZeneca, and Janssen Pharmaceuticals Inc.
Bristol Myers Squibb (BMS) is a biopharmaceutical company that is helping – outpatients in succeeding aliments by delivering innovative products. It has owned innovative drugs such as OPDIVO Immunotherapy Drugs for a wider range of diseases.
Market competitiveness is expected to increase during the forecast period as the vendors constantly focus on expanding their product portfolios.

Key Vendors
F. Hoffmann-La Roche
Bristol Myers Squibb Company
Merck & Co., Inc.
Janssen Pharmaceuticals, Inc.

Other Prominent Vendors
Alexion Pharmaceuticals
Eli Lilly and Company
Elusys Therapeutics, Inc
Gilead Sciences, Inc
NBE Therapeutics
Pfizer, Inc
Seagen Inc.
Teva pharmaceuticals

1. How big is the immunotherapy drugs market?
2. What are the products segmentation in the immunotherapy drugs market?
3. Which region has the highest growth rate for the immunotherapy drugs industry?
4. What are the latest trends in the global immunotherapy drugs market?
5. What is the impact of COVID-19 on the immunotherapy drugs market?
6. Who are the prominent players in the global immunotherapy drugs market?
7. Which countries are the major contributor for Cancer Immunotherapy Drugs Market in APAC?

1 Research Methodology
2 Research Objectives
3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.1.3 Market Estimation Caveats
4.2 Base Year
4.3 Scope of the Study
4.3.1 Market Segmentation by Geography
4.3.2 Market Segmentation by Product
4.3.3 Market Segmentation by Application
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market at a Glance
7 Introduction
7.1 Overview
8 Market Opportunities & Trends
8.1 Launch of Next-Generation Immunotherapies
8.2 COVID-19 as Growth Catalyst
8.3 Investment in R&D Activities
8.4 Mergers & Acquisitions
9 Market Growth Enablers
9.1 Prevalence of Cancer & Autoimmune Diseases
9.2 Approval of Novel Immunotherapy Drugs
9.3 Surge in Adoption of Car T-Cell Therapies
10 Market Restraints
10.1 Expensive Nature of Immunotherapy
10.2 Personalized Approach Through Biomarkers
10.3 Time-Consuming Production Cycle
11 Market Landscape
11.1 Market Overview
11.2 Market Size & Forecast
11.2.1 Geographic Insights
11.2.2 Application Insights
11.2.3 Product Insights
11.3 Impact of COVID-19 on Immunotherapy Drugs
11.4 Porter’s Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Product
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Monoclonal Antibody
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.4 Immune System Modulators
12.4.1 Market Overview
12.4.2 Market Size & Forecast
12.5 Car T-Cell Therapy
12.5.1 Market overview
12.5.2 Market Size & Forecast
12.6 Others
12.6.1 Market overview
12.6.2 Market Size & Forecast
13 Application
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Cancer
13.3.1 Market overview
13.3.2 Market Size & Forecast
13.4 Autoimmune & Inflammatory Diseases
13.4.1 Market overview
13.4.2 Market Size & Forecast
13.5 Others
13.5.1 Market overview
13.5.2 Market Size & Forecast
14 Geography
14.1 Market Snapshot & Growth Engine
14.2 Geographic Overview
15 North America
15.1 Market Overview
15.2 Market Size & Forecast
15.3 Key Countries
15.3.1 US: Market Size & Forecast
15.3.2 Canada: Market Size & Forecast
16 Europe
16.1 Market Overview
16.2 Market Size & Forecast
16.3 Key Countries
16.3.1 Germany: Market Size & Forecast
16.3.2 UK: Market Size & Forecast
16.3.3 France: Market Size & Forecast
16.3.4 Italy: Market Size & Forecast
16.3.5 Spain: Market Size & Forecast
17 Asia Pacific
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Key Countries
17.3.1 China: Market Size & Forecast
17.3.2 India: Market Size & Forecast
17.3.3 Japan: Market Size & Forecast
17.3.4 Australia: Market Size & Forecast
17.3.5 South Korea: Market Size & Forecast
18 Latin America
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Key Countries
18.3.1 Brazil: Market Size & Forecast
18.3.2 Mexico: Market Size & Forecast
18.3.3 Argentina: Market Size & Forecast
19 Middle East & Africa
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Key Countries
19.3.1 South Africa: Market Size & Forecast
19.3.2 Saudi Arabia: Market Size & Forecast
19.3.3 Turkey: Market & Forecast
20 Competitive Landscape
20.1 Competition Overview
20.2 Market Share Analysis
20.2.1 F. Hoffmann-La Roche AG
20.2.2 Bristol Myers Squibb
20.2.3 Merck & Co., Inc.
20.2.4 GlaxoSmithKline
20.2.5 Novartis
20.2.6 AstraZeneca
20.2.7 Janssen Pharmaceuticals
21 Key Company Profiles
21.1 F. Hoffmann-La Roche
21.1.1 Business Overview
21.1.2 Product Offerings
21.1.3 Key Strategies
21.1.4 Key Strengths
21.1.5 Key Opportunities
21.2 Bristol-Myers Squibb Company
21.2.1 Business Overview
21.2.2 Product Offerings
21.2.3 Key Strategies
21.2.4 Key Strengths
21.2.5 Key Opportunities
21.3 Merck & Co., Inc.
21.3.1 Business Overview
21.3.2 Product Offerings
21.3.3 Key Strategies
21.3.4 Key Strengths
21.3.5 Key Opportunities
21.4 GlaxoSmithKline
21.4.1 Business Overview
21.4.2 Product Offerings
21.4.3 Key Strategies
21.4.4 Key Strengths
21.4.5 Key Opportunities
21.5 Novartis
21.5.1 Business Overview
21.5.2 Product Offerings
21.5.3 Key Strategies
21.5.4 Key Strengths
21.5.5 Key Opportunities
21.6 Astrazeneca
21.6.1 Business Overview
21.6.2 Product Offerings
21.6.3 Key Strategies
21.6.4 Key Strengths
21.6.5 Key Opportunities
21.7 Janssen Pharmaceuticals, Inc.
21.7.1 Business Overview
21.7.2 Product Offerings
21.7.3 Key Strategies
21.7.4 Key Strengths
21.7.5 Key Opportunities
22 Other Prominent Vendors
22.1 Abbvie
22.1.1 Business Overview
22.1.2 Product Offerings
22.2 Alexion Pharmaceuticals
22.2.1 Business Overview
22.2.2 Product Offerings
22.3 Amgen
22.3.1 Business Overview
22.3.2 Product Offerings
22.4 Bayer
22.4.1 Business Overview
22.4.2 Product Offerings
22.5 Dendreon
22.5.1 Business Overview
22.5.2 Product Offerings
22.6 Dynavax
22.6.1 Business Overview
22.6.2 Product Offerings
22.7 Eli Lilly & Company
22.7.1 Business Overview
22.7.2 Product Offerings
22.8 Elusys Therapeutics, Inc.
22.8.1 Business Overview
22.8.2 Product Offerings
22.9 Gilead Sciences, Inc.
22.9.1 Business Overview
22.9.2 Product Offerings
22.10 NBE Therapeutics
22.10.1 Business Overview
22.11 Pfizer, Inc.
22.11.1 Business Overview
22.11.2 Product Offerings
22.12 Sanofi
22.12.1 Business Overview
22.12.2 Product Offerings
22.13 Seagen Inc.
22.13.1 Business Overview
22.13.2 Product Offerings
22.14 Teva Pharmaceuticals
22.14.1 Business Overview
22.14.2 Product Offerings
23 Report Summary
23.1 Key Takeaways
23.2 Strategic Recommendations
24 Quantitative Summary
24.1 Market by Geography
24.2 Market by Product
24.3 Market by Application
25 Appendix
25.1 Abbreviations

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook